BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Schizophrenia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for schizophrenia: 84 (51 sponsors; 18 newly posted in the last 180 days, 6 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 20.2, rank 29 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 17, Phase 2 18, Phase 3 30, Phase 4 3, N/A 15.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Neurocrine Biosciences NBIX6P2 1, P3 4, P4 100
Bristol-Myers Squibb BMY8P3 3, NA 3, P1 1, P4 110
Karuna Therapeutics, Inc., a Bristol Myers Squibb company3P3 311
Alkermes, Inc. ALKS2P3 200
Bostal Drug Delivery Co., Ltd new entrant2P3 220
Jiangsu Hansoh Pharmaceutical Co., Ltd. new entrant2P3 220
LB Pharmaceuticals Inc. LBRX2P3 200
Otsuka Pharmaceutical Co., Ltd.2P3 200
Intra-Cellular Therapies, Inc.2P3 1, P2 100
Otsuka Pharmaceutical Development & Commercialization, Inc.2P1 1, P3 101
Vanda Pharmaceuticals VNDA2P3 1, P4 100
Chengdu Kanghong Pharmaceutical Group Co., Ltd.1P3 100
Gedeon Richter Plc.1P3 101
Minerva Neurosciences NERV1P3 100
Newron Pharmaceuticals SPA1P3 101
Qilu Pharmaceutical Co., Ltd.1P3 100
Reviva Pharmaceuticals RVPH1P3 100
SyneuRx International (Taiwan) Corp1P3 100
Luye Pharma Group Ltd.5P1 4, P2 100
MapLight Therapeutics MPLT3P2 300
Vigonvita Life Sciences3P1 2, P2 110
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.2NA 201
Eli Lilly and Company LLY2NA 1, P2 100
Novartis Pharmaceuticals NVS2P1 1, P2 110
AbbVie ABBV1P2 100

New-entrant sponsors: Bostal Drug Delivery Co., Ltd, Jiangsu Hansoh Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-15 est.P3Gedeon Richter Plc.NCT03817502 Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaSchizophreniarecruiting330
2026-12-31 est.P1/P2Mapi Pharma Ltd.NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for TreatmenSchizophrenia; Bipolar I Disorder; Major Depressive Disorderrecruiting24

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-12-12PDUFA date (company-disclosed)pendingVanda Pharmaceuticals Inc. VNDAimsidolimabPDUFA December 12, 2026 - Vanda Pharmaceuticals Inc. (imsidolimab)

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2NeuShen TherapeuticsNCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of SchizophreniaSchizophrenia(Acute)enrolling by invitation150
2026-10-23 est.P3Qilu Pharmaceutical Co., Ltd.NCT06799559 Study on the Efficacy and Safety of QLM1016 in SchizophreniaSchizophreniaactive not recruiting402
2026-10-20 est.P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06894212 A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaSchizophreniaactive not recruiting538
2026-09-30 est.P2/P3SyneuRx International (Taiwan) CorpNCT03094429 An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBenĀ®, as an ARefractory Schizophreniarecruiting287
2026-09-09P2Kynexis B.V.NCT07191483 A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaCognitive Impairment Associated With Schizophrenia (CIAS)completed149
2026-09 est.P3Alkermes, Inc. ALKSNCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderSchizophrenia; Bipolar I Disorderrecruiting220
2026-06-04P2MapLight Therapeutics MPLTNCT07038876 A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaSchizophreniacompleted307
2026-06 est.P3Chengdu Kanghong Pharmaceutical Group Co., Ltd.NCT06589817 A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute SchizophreniaAcute Schizophrenianot yet recruiting376

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "schizophrenia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.